This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of -550% and 6.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 31.03% and 18.62%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 100% and 6.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice
by Zacks Equity Research
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stocks to Buy for January 5th
by Zacks Equity Research
ORGO, CALM and NET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2024.
New Strong Buy Stocks for January 5th
by Zacks Equity Research
ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.
Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights Organogenesis, Riskified, Hooker Furniture, Stoneridge and VirTra
by Zacks Equity Research
Organogenesis, Riskified, Hooker Furniture, Stoneridge and VirTra are included in this Analyst Blog.
5 Reasons Why Small-Cap Stocks Can Surge in 2024: 5 Top Picks
by Sanghamitra Saha
Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Against this backdrop, Organogenesis (ORGO), Riskified (RSKD), Hooker Furniture Corporation (HOFT), Stoneridge (SRI) and VirTra (VTSI) emerge as winning picks.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Organogenesis (ORGO)
by Zacks Equity Research
Organogenesis (ORGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Strength Seen in Inotiv, Inc. (NOTV): Can Its 34.5% Jump Turn into More Strength?
by Zacks Equity Research
Inotiv, Inc. (NOTV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 3.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -15.69% and 1.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Stock Jumps 5.3%: Will It Continue to Soar?
by Zacks Equity Research
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Organogenesis (ORGO) Q1 Earnings Lag Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of -80% and 2.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aziyo Biologics, Inc. (AZYO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of 3.23% and 6.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Foghorn Therapeutics Inc. (FHTX): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Organogenesis (ORGO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 412.50% and 3.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Stock Jumps 7.4%: Will It Continue to Soar?
by Zacks Equity Research
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Abbott (ABT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Abbott (ABT) and Organogenesis (ORGO) have performed compared to their sector so far this year.
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 50.00% and 1.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?